Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico

Ethnicity and Disease

Volumn 18, Issue 2 SUPPL. 2, 2008, Pages

  Molina, María J ^a   Mayor, Angel M ^a   Franco, Alejandro E ^b   Morell, Carlos A ^b   López, Miguel A ^b   Vila, Luis M ^a,c  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b (Independent license of BC/BSA)   (Puerto Rico)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Healthcare utilization; Prescription pattern; Puerto rico; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; COMPLEMENT; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DAPSONE; DNA ANTIBODY; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE MARKER; EMERGENCY WARD; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FISHER EXACT TEST; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERNATIONAL CLASSIFICATION OF DISEASES; KIDNEY DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PHYSICIAN; PRESCRIPTION; PUERTO RICO; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; DEMOGRAPHY; PRIMARY HEALTH CARE; STATISTICS; UTILIZATION REVIEW;

ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; DEMOGRAPHY; FEMALE; HEALTH SERVICES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; PUERTO RICO; RHEUMATOLOGY;

EID: 52149108506     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mills JA. Systemic lupus erythematosus. N Engl J Med. 1994;330:1871-1879.
2. Alarcón GS, Mc Gwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three groups. VII. Predictors of early mortality in the LUMINA cohott. LUMINA study group. Arthritis Rheum. 2001;45:191-202.
3. Pons-Estel BA, Catoggio LJ, Catdiel MH, et al. Grupo Latinoamericano de Estudio de Lupus. The GLADEL multinational Latin American prospective inception cohort of 1, 214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanic." Medicine (Baltimore). 2004;83: 1-17.
4. Gladman DD, Urowitz MB, EsdaileJM, et al. American College Rheumatology Ad Hoc Committee on SLE Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;42:1785-1796.
5. Gamez-Nava J, Gonzalez-Lopez L, Davis P, Suarez-Almazor ME. Referral and diagnosis of common rheumatic disease by primary care physicians. Br J Rheumatol. 1998;37: 1215-1219.
6. Urowitz MB, Kagal A, Rahman P, Gladman DD. Role of specialty care in the management of patients with systemic lupus erythematosus. J Rheumatol. 2002;29:1207-1210.
7. Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 2005;52:2485-2494.
8. Vilá LM, Alarcón GS, McGwin G Jr, Bastian HM, Fessler BJ, Reveille JD, for the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol. 2005;32:2150- 2155.
9. Donald F, Ward MM. Evaluative laboratory testing practices of United States rheumatologists. Arthritis Rheum. 1998;41:725-729.
10. Zink A, Fischer-Betz R, Thiele K, et al. for the German Collaborative Arthritis Centres. Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the national database of the German Collaborative Arthritis Centres. Lupus. 2004;13:529-536.
11. Tarn LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol. 2000;27: 2142-2145.
12. Fessler BJ, Alarcón GS, McGwin G Jr, et al. for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473-1480.
13. Molad Y, Gorshtein A, Wysenbeek AJ, et al. Ptotective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002;11:356-361.
14. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308.
15. D'Cruz D. Antimalarial therapy: a panacea fot mild lupus? Lupus. 2001;10:148-151.
16. Ho KT, Ahn CW, Alarcón GS, et al. for the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford). 2005;44:1303-1307.
17. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalafial drugs is enhanced in patients with systemic lupus erythematosus. J Rheumatol. 1999;26:325-330.
18. Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28:102-108.
19. Tsakonas E, Joseph L, Esdaile JM, et al. and The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbation in systemic lupus erythematosus. Lupus. 1998;7: 80-85.
20. Bae SC, Hashimoto H, Karlson EW, Liang MH, Daltroy LH. Variable effects of social support by race, economic status and disease activity in systemic lupus etythematosus. J Rheumatol. 2001;28:1245-1251.